Page 35 - Term Sheet News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PRESS RELEASE – INSIDE INFORMATION Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment as a first decisive, financing step towards a Phase 3 clinical trial for its ground-breaking auto-immune medication, a first-in-class drug oral arsenic salt. Mont-Saint-Guibert, Belgium, December 6, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious aut

“Exits through acquisition are critical to creating and maintaining a self-sustaining cycle of innovation,” a letter singed by the firms reads.

An interesting, but little-known compliance requirement makes private equity and VC firm employees register as lobbyists.

In 2018, Khosla Ventures wrote a $50 million check to OpenAI, though he says it was “almost impossible to diligence.”

The combined firm will have a collective investment value of over $9.7 billion.